Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine phosphate 4Cyclosporine 3Cyclophosphamide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3ruxolitinib 2fludarabine 2Whole-Body Irradiation 2Stem Cell Transplantation 2Radiotherapy 2Methylprednisolone 2Busulfan 2Antilymphocyte Serum 2nelarabine 1arsenous acid 1anagrelide 1Watchful Waiting 1Thiotepa 1Tetradecanoylphorbol Acetate 1Surveys and Questionnaires 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Observation 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Moxifloxacin 1Morphine 1Methotrexate 1Methadone 1Liposomes 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thrombocythemia, Essential × CPX-351 × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡